Taranabant for obesity discontinued by Merck
Merck Discontinues Development of Investigational Medicine Taranabant for Obesity – Merck & Co., Inc. will not seek regulatory approval for taranabant, an investigational medicine, to treat obesity and is discontinuing its Phase III clinical development program for taranabant for obesity.